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San Raffaele Scientific Institute, Milan, ItalyMolecular-based, rapid drug susceptibility tests are needed
to guide the appropriate use of the new drugs and new ther-
apeutic regimens at the programmatic level, and to prevent
a further increase in the incidence of drug-resistant TB.
Experts have recognized the need for a global, curated and
standardized analysis and data-sharing platform that pro-
vides a one-stop data source for clinically relevant genotypic
and phenotypic information on Mycobacterium tuberculosis
(MTB). To this purpose, the Relational Sequencing TB Data
Platform (ReSeqTB) consortium has critically reviewed the
most inclusive set of published data on mutations associated
with drug resistance in MTB to date, and has graded a com-
prehensive list of globally prevalent mutations based on the
strength of their association with drug resistance. ReSeqTB
serves as a single repository for the compilation, curation,
and validation of existing and newly created sequences and
metadata on MTB strains and will use the currently reviewed
data set, validated by international experts, as a starting point
until sufficient new sequence data is accumulated. This ini-
tiative is supported by a global partnership of academic insti-
tutions, public health agencies and non-governmental
organizations including the Critical Path Institute, FIND, the
World Health Organization, the New Diagnostics Working
Group, the U.S. Centers for Disease Control and Prevention,
and the National Institute of Allergy and Infectious Diseases
and it is financially supported by the Bill & Melinda Gates
Foundation.
Key strengths of the ReSeqTB Database include:
 A user-friendly interface designed for non-expert or
expert operability. A standardized and validated analysis pipeline for
variant analyses of MTB NGS data.
 Access to data beyond the published literature with
dynamic and iterative updates of new data generated
by global surveillance and clinical trials.
 Awell-developed legal structure to ensure intellectual
property rights and data ownership remain with
contributors.
 A structured data sharing architecture to restrict
access to sensitive or unpublished data sets.
 Meta data standardization using CDISC: supports glo-
bal, platform-independent data standards that enable
information system interoperability.
 An emphasis on data quality and rigorous, expert
curation with multiple quality control checks for
WGS and other meta data.
 Validation of NGS analysis output by an expert com-
mittee with grading of resistance conferring muta-
tions based on rigorous statistical standards.
 Regulatory-compliant analysis pipeline and database
architecture.
Successful execution of such an extensive database plat-
form requires substantial collaboration from scientists inves-
tigating the genetic basis for drug resistance worldwide, and
from developers with expertise in database design and
implementation.
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